News | Proton Therapy | October 27, 2015

IBA Announces Upgrades to Penn Medicine Proton Therapy Center Equipment

New advances include cone beam CT, pencil beam scanning technology

Penn Medicine, IBA upgrades, Roberts Proton Therapy Center, PBS, CBCT

October 27, 2015 — IBA announced that longtime customer and research partner Penn Medicine has upgraded the equipment of its Roberts Proton Therapy Center with the latest innovations in proton therapy treatment. This upgrade to the newest technologies will allow Penn Medicine’s staff to continue to offer top-level proton radiation therapy services to an increasing number of patients and to further advance the clinical application of proton therapy.

Penn Medicine treated its first proton patient in March 2010. Research collaborations with IBA are extensive, with Penn Medicine contributing to the research on pencil beam scanning (PBS) protocols and cone beam computed tomography (CBCT), among others. Penn Medicine’s proton therapy facility and experts also play a key role in IBA’s training program, sharing knowledge and experience to contribute to the education of the entire proton therapy community.

Recent acquisitions by the Roberts Proton Therapy Center include:

  • Having taken part in the development and optimization of IBA’s CBCT, Penn Medicine has opted to purchase this image guidance tool, which ensures increased accuracy in patient positioning and brings the center one step closer to adaptive proton therapy treatment;
  • Penn Medicine will replace one of its universal nozzles to a dedicated PBS nozzle. This brings Penn Medicine to a total of four PBS treatment rooms, with one double scattering treatment room remaining. It will allow Penn clinicians to offer the most accurate delivery of proton therapy currently available to a larger number of patients, while maintaining the advantage double scattering provides when treating moving targets. This adapted configuration provides Penn Medicine with the option to cover a very broad range of indications, with fixed as well as moving targets; and
  • For research purposes, Penn Medicine will also deploy the Universal Monitoring Interface (UMI) and Adapt Analytics software. These software applications are used to monitor how much time is spent on and by the patient at different treatment stages. The aim of this research is to improve the workflow efficiency in order to optimize throughput. Ultimately, it will allow more patients, at Penn Medicine and elsewhere, to benefit from proton therapy treatment.

The current Penn Medicine upgrade exceeds $3 million USD, and IBA still has a general pipeline left of $7 million.

James Metz, M.D., chair of Penn Medicine Department of Radiation Oncology, commented, “The clinical application of proton therapy is a medical field in full evolution. At Penn Medicine, we believe in its potential and are fully committed to helping its realization, leveraging topnotch technology to make sure that as many eligible patients as possible can benefit from this radiation therapy modality, now and in the future.”

For more information: www.iba-worldwide.com

Related Content

News | Computed Tomography (CT) | May 21, 2018
The Istituto Oncologico Veneto (IOV) in Padua, Italy, has acquired MILabs’ latest-generation Versatile Emission...
Mercy Signs Multi-System, Multi-Hospital Agreement for Accuray Radiotherapy Systems
News | Radiation Therapy | May 16, 2018
Accuray Inc. signed a multi-system, multi-hospital agreement with Mercy for the acquisition of Accuray Radixact and...
ViewRay Unveils New Soft Tissue Visualization Technologies for MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | April 30, 2018
ViewRay Inc. announced new magnetic resonance imaging (MRI) technologies under development for its MRIdian Linac...
MedStar Georgetown Conducts World's First Hyperscan Proton Therapy Treatment
News | Proton Therapy | April 27, 2018
For the first time, cancer patients in the Washington, D.C. metropolitan region have access to proton therapy, now...
Designed to support a broad range of planning and delivery technologies, SunCheck 2.0 streamlines and standardizes workflows, allowing greater overall focus on patient safety.
Technology | Quality Assurance (QA) | April 27, 2018
Sun Nuclear Corp. released significant new functionality for its SunCheck Platform for patient and machine quality...
RayStation Users Win Inaugural Treatment Planning World Championships
News | Treatment Planning | April 27, 2018
In the first World Championships of Treatment Planning, arranged by radiation oncology analytics company ProKnow and...
Brainlab Introduces New Hi-Res Planning Algorithm for VersaHD
News | Treatment Planning | April 24, 2018
Brainlab announced the implementation of a software solution that can achieve better radiation dose conformity around...
Shorter Radiotherapy Courses Safe and Effective for Prostate Cancer
News | Prostate Cancer | April 23, 2018
Radiotherapy given in high doses over a shorter period of time is safe and effective for prostate cancer patients,...
Elekta Expands Mosaiq Oncology Information System With PalabraApps
News | Oncology Information Management Systems (OIMS) | April 20, 2018
April 20, 2018 — Elekta announced that it is making a strategic investment in PalabraApps LLC to advance the developm
This image, taken with Canon's Aquilion One, shows a lung with metastases from bowel cancer.

This image, taken with Canon’s Aquilion One, shows a lung with metastases from bowel cancer. Image courtesy of Canon.

Feature | Lung Cancer | April 18, 2018 | Jeff Zagoudis
In recent years, low-dose computed tomography (CT) screening has emerged as a proven, effective method to detect lung
Overlay Init